122 related articles for article (PubMed ID: 37542818)
1. In-vivo and human evidence for potential efficacy of therapeutic polyclonal RSV neutralizing antibodies for palivizumab-resistant RSV infections.
Ramirez KA; Mond J; Papenburg J; Boivin G; Gilbert BE; Falsey AR; Bagga B; DeVincenzo JP
Virology; 2023 Sep; 586():115-121. PubMed ID: 37542818
[TBL] [Abstract][Full Text] [Related]
2. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
[TBL] [Abstract][Full Text] [Related]
3. RI-002, an intravenous immunoglobulin containing high titer neutralizing antibody to RSV and other respiratory viruses for use in primary immunodeficiency disease and other immune compromised populations.
Wasserman RL; Greener BN; Mond J
Expert Rev Clin Immunol; 2017 Dec; 13(12):1107-1119. PubMed ID: 29035131
[TBL] [Abstract][Full Text] [Related]
4. Compassionate use experience with high-titer respiratory syncytical virus (RSV) immunoglobulin in RSV-infected immunocompromised persons.
Falsey AR; Koval C; DeVincenzo JP; Walsh EE
Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28054734
[TBL] [Abstract][Full Text] [Related]
5. Comparative Therapeutic Potential of ALX-0171 and Palivizumab against Respiratory Syncytial Virus Clinical Isolate Infection of Well-Differentiated Primary Pediatric Bronchial Epithelial Cell Cultures.
Broadbent L; Parke HG; Ferguson LJ; Millar A; Shields MD; Detalle L; Power UF
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31767728
[TBL] [Abstract][Full Text] [Related]
6. Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients.
Chávez-Bueno S; Mejías A; Merryman RA; Ahmad N; Jafri HS; Ramilo O
Pediatr Infect Dis J; 2007 Dec; 26(12):1089-93. PubMed ID: 18043443
[TBL] [Abstract][Full Text] [Related]
7. In vivo selection of respiratory syncytial viruses resistant to palivizumab.
Zhao X; Sullender WM
J Virol; 2005 Apr; 79(7):3962-8. PubMed ID: 15767398
[TBL] [Abstract][Full Text] [Related]
8. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn.
Pediatrics; 1998 Nov; 102(5):1211-6. PubMed ID: 9794957
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model.
Zeitlin L; Bohorov O; Bohorova N; Hiatt A; Kim DH; Pauly MH; Velasco J; Whaley KJ; Barnard DL; Bates JT; Crowe JE; Piedra PA; Gilbert BE
MAbs; 2013; 5(2):263-9. PubMed ID: 23396091
[TBL] [Abstract][Full Text] [Related]
10. Development of bioluminescence imaging of respiratory syncytial virus (RSV) in virus-infected live mice and its use for evaluation of therapeutics and vaccines.
Fuentes S; Arenas D; Moore MM; Golding H; Khurana S
Vaccine; 2017 Jan; 35(4):694-702. PubMed ID: 27989627
[TBL] [Abstract][Full Text] [Related]
11. Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen.
Claydon J; Sur A; Callejas A; Ladd M; Kwan E; Taylor R; Turvey SE; Solimano A; Lavoie PM; Marr N
PLoS One; 2017; 12(4):e0176152. PubMed ID: 28437470
[TBL] [Abstract][Full Text] [Related]
12. Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy.
Hiatt A; Bohorova N; Bohorov O; Goodman C; Kim D; Pauly MH; Velasco J; Whaley KJ; Piedra PA; Gilbert BE; Zeitlin L
Proc Natl Acad Sci U S A; 2014 Apr; 111(16):5992-7. PubMed ID: 24711420
[TBL] [Abstract][Full Text] [Related]
13. Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab.
Wu H; Pfarr DS; Losonsky GA; Kiener PA
Curr Top Microbiol Immunol; 2008; 317():103-23. PubMed ID: 17990791
[TBL] [Abstract][Full Text] [Related]
14. Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats.
Smith G; Raghunandan R; Wu Y; Liu Y; Massare M; Nathan M; Zhou B; Lu H; Boddapati S; Li J; Flyer D; Glenn G
PLoS One; 2012; 7(11):e50852. PubMed ID: 23226404
[TBL] [Abstract][Full Text] [Related]
15. Analysis of respiratory syncytial virus fusion protein from clinical isolates of Korean children in palivizumab era, 2009-2015.
Choi SH; Park KS; Kim YJ
J Infect Chemother; 2019 Jul; 25(7):514-519. PubMed ID: 30885457
[TBL] [Abstract][Full Text] [Related]
16. Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection.
Brady T; Cayatte C; Roe TL; Speer SD; Ji H; Machiesky L; Zhang T; Wilkins D; Tuffy KM; Kelly EJ
Front Immunol; 2023; 14():1283120. PubMed ID: 37901217
[TBL] [Abstract][Full Text] [Related]
17. [Prophylaxis of respiratory syncytial virus (RSV) in preterm infants with/without bronchopulmonary dysplasia: hyperimmune globulin (RSV-IGIV) and palivizumab (MEDI-493)].
Resch B; Müller W
Klin Padiatr; 1999; 211(6):450-5. PubMed ID: 10592925
[TBL] [Abstract][Full Text] [Related]
18. A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats.
Rostad CA; Stobart CC; Gilbert BE; Pickles RJ; Hotard AL; Meng J; Blanco JCG; Moin SM; Graham BS; Piedra PA; Moore ML
J Virol; 2016 Aug; 90(16):7508-7518. PubMed ID: 27279612
[TBL] [Abstract][Full Text] [Related]
19. Restrictive Palivizumab Use Does Not Lead to Increased Morbidity and Mortality in Pediatric Hematopoietic Stem Cell Transplantation Patients.
Teusink-Cross A; Davies SM; Danziger-Isakov L; El-Bietar J; Grimley MS
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1904-1906. PubMed ID: 27422147
[TBL] [Abstract][Full Text] [Related]
20. Treatment with novel RSV Ig RI-002 controls viral replication and reduces pulmonary damage in immunocompromised Sigmodon hispidus.
Boukhvalova M; Blanco JC; Falsey AR; Mond J
Bone Marrow Transplant; 2016 Jan; 51(1):119-26. PubMed ID: 26367224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
